Condition: Von Willebrand Disease, Type 3 · Sponsor: Hoffmann-La Roche
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Participants on prior standard of care (SOC) on-demand therapy will be assessed via a randomized comparison (Arm A - emicizumab prophylaxis and Arm B - continuation of SOC on-demand therapy), while participants on prior SOC prophylactic therapy (Arm C - emicizumab prophylaxis) will be assessed via intra-participant analysis with data obtained from the preceding non-interventional study (NIS), WP45335 (NCT06883240).
This description comes directly from the study's public registry record.
Reference Study ID Number: WP45338 https://forpatients.roche.com/ · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| UC Davis | Sacramento, California, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| University of Minnesota Medical Center | Minneapolis, Minnesota, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Virginia Commonwealth University | Richmond, Virginia, United States | Recruiting |
| UZ Leuven Gasthuisberg | Leuven, Belgium | Recruiting |
| The Hospital for Sick Children | Toronto, Ontario, Canada | Recruiting |
| McGill University Health Center | Montreal, Quebec, Canada | Recruiting |
| IPS SURA Industriales Medellín | Medellín, Colombia | Recruiting |
| Hopital Claude Huriez - CHU Lille | Lille, France | Recruiting |
| Groupe Hospitalier Necker Enfants Malades | Paris, France | Recruiting |
| Universitätsklinikum Bonn | Bonn, Germany | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06998524